Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $102.46 USD
Change Today -0.85 / -0.82%
Volume 1.2M
NVS On Other Exchanges
New York
SIX Swiss Ex
SIX Swiss Ex
As of 8:04 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by NOVARTIS AG-SPONSORED ADR (NVS) in the last 6 months

Announced 03/30/15
25.00M for Aduro BioTech, Inc.
Private Placement

Aduro BioTech, Inc. announced that it has received $25 million in a round of funding from new investor Novartis AG on March 30, 2015. As a result of the transaction, the investor has acquired 2.7% stake in the company. The investor has also committed to invest another $25 million at a future date,

NVS's price was unchanged after the transaction was announced on 03/30/15.
Investor / Buyer
Novartis AG
Announced 03/13/15
Valneva SE

GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.

NVS's price was unchanged after the transaction was announced on 03/13/15.
Investor / Buyer
GlaxoSmithKline plc
Creditor / Lender
Novartis AG
Announced 01/7/15
11.00M for Caribou Biosciences, Inc.
Private Placement

Caribou Biosciences, Inc. announced that it has received undisclosed amount in series A round of equity funding from Novartis AG on January 7, 2015.

NVS's price was unchanged after the transaction was announced on 01/7/15.
Investor / Buyer
5 Prime Ventures
Fidelity Biosciences
Mission Bay Capital LLC
Novartis AG
Announced 11/18/14
15.00M for Intellia Therapeutics Inc.
Private Placement

Intellia Therapeutics announced that it has received $15 million in its first round of funding from new investors Atlas Venture L.P. and the research arm of Novartis AG. on November 18, 2014. Atlas Venture L.P. invested in the formation of the company.

NVS's price was unchanged after the transaction was announced on 11/18/14.
Investor / Buyer
Atlas Venture L.P.
Novartis AG
Announced 10/26/14
275.00M for Novartis AG, Influenza Vaccines Business

bioCSL Inc. entered into a definitive agreement to acquire influenza vaccines business from Novartis AG (SWX:NOVN) for approximately $280 million on October 26, 2014. The Novartis influenza vaccines unit will be combined with bioCSL. For the year ended December 31, 2013, influenza vaccines business posted sales of $527 million. The transaction requires regulatory approvals and is expected to close in the second half of 2015. Tim Duncan of Hintons & Associates acted as ...
Read More

NVS's price was unchanged after the transaction was announced on 10/26/14.
Investor / Buyer
bioCSL Inc.
Creditor / Lender
Novartis AG

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $102.46 USD -0.85

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $101.38 USD -1.96
Johnson & Johnson $99.58 USD -0.21
Merck & Co Inc $56.88 USD -0.96
Pfizer Inc $35.04 USD -0.15
Roche Holding AG SFr.270.20 CHF -5.10
View Industry Companies

Industry Analysis


Industry Average

Valuation NVS Industry Range
Price/Earnings 23.7x
Price/Sales 4.6x
Price/Book 3.5x
Price/Cash Flow 27.1x
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at